Management ChangeOct 29, 2026, 05:11 PM
Teva Pharma Appoints Dr. David J. Brailer to Board of Directors
AI Summary
Teva Pharmaceutical Industries Ltd. announced the election of Dr. David J. Brailer to its Board of Directors, effective November 3, 2026. Dr. Brailer, who brings a wealth of experience from various health-tech and healthcare leadership roles, including his recent positions at The Cigna Group, is expected to contribute to the Human Resources and Compensation and Compliance Committees. He will serve until the company's 2027 annual meeting of shareholders and will receive compensation consistent with other non-executive directors.
Key Highlights
- Dr. David J. Brailer elected to Teva's Board of Directors, effective November 3, 2026.
- Dr. Brailer will serve until Teva's 2027 annual meeting of shareholders.
- He is expected to serve on the Human Resources and Compensation and Compliance Committees.
- Dr. Brailer brings extensive experience from health-tech and healthcare companies, including Cigna Group and Duke Margolis Health Policy Institute.
- He previously served on the boards of Prolacta Bioscience, Inc. and Walgreens Boots Alliance, Inc.
Price Impact
More from TEVA